KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Cash (2016 - 2025)

AbbVie (ABBV) has disclosed Change in Cash for 14 consecutive years, with -$400.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 76.92% to -$400.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$295.0 million, a 95.95% increase, with the full-year FY2025 number at -$295.0 million, up 95.95% from a year prior.
  • Change in Cash was -$400.0 million for Q4 2025 at AbbVie, up from -$838.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $5.3 billion in Q1 2024 to a low of -$5.9 billion in Q3 2024.
  • A 5-year average of -$161.0 million and a median of -$436.5 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 535.78% in 2021, then surged 310.96% in 2024.
  • AbbVie's Change in Cash stood at -$2.4 billion in 2021, then dropped by 8.0% to -$2.6 billion in 2022, then surged by 82.02% to -$473.0 million in 2023, then tumbled by 266.38% to -$1.7 billion in 2024, then skyrocketed by 76.92% to -$400.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Change in Cash are -$400.0 million (Q4 2025), -$838.0 million (Q3 2025), and $1.3 billion (Q2 2025).